$AMRX News

Zambon And Amneal's Hopledo Receives Positive CHMP Opinion For Parkinson's Disease, European Launch Expected From October 2026

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Amneal Pharmaceuticals Announces New Interim Results From Phase 4 Study Reinforcing Reported Benefits Of Parkinson's Treatment Crexont

Amneal Pharmaceuticals Romidepsin Injection Solution Receives FDA Approval

Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $16

3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)

Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?

2 Reasons AMRX is Risky and 1 Stock to Buy Instead

Amneal Pharmaceuticals' (NASDAQ:AMRX) Solid Earnings Are Supported By Other Strong Factors

Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

Amneal Reports First Quarter 2026 Financial Results

Amneal Pharmaceuticals Kashiv Deal Puts Biosimilar Growth And Valuation In Focus

Do Options Traders Know Something About Amneal Stock We Don't?

UBS Initiates Coverage of Amneal Pharmaceuticals (AMRX) With a Bullish Outlook

Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"

Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?

Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?

Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price Cooldown

Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push